DOCSLIB.ORG

Enhancing Everyday Life Annual Report 2012

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enhancing Everyday Life Annual Report 2012 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 0775) Enhancing Everyday Life Annual Report 2012 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong Tel: (852) 2126 1212 Fax: (852) 2126 1211 www.ck-lifesciences.com Annual Report 2012 About CK Life Sciences CK Life Sciences Int’l., (Holdings) Inc. is listed on The Stock Exchange of Hong Kong Limited. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, commercialisation, marketing and sale of health and agriculture-related products. Products developed by CK Life Sciences are categorised into the areas of human health and environmental sustainability. A number of inventions have been granted patents by the US Patent and Trademark Office. CK Life Sciences is a member of the Cheung Kong Group. Contents 2 Chairman’s Statement 6 Business Review Agriculture-related Business Nutraceutical Business Pharmaceutical Business 20 Long Term Development Strategy 21 Financial Summary 22 Financial Review 24 Directors and Key Personnel 31 Report of the Directors 44 Independent Auditor’s Report 46 Consolidated Income Statement 47 Consolidated Statement of Comprehensive Income 48 Consolidated Statement of Financial Position 50 Consolidated Statement of Changes in Equity 51 Consolidated Statement of Cash Flows 53 Notes to the Consolidated Financial Statements 114 Principal Subsidiaries 119 Principal Associate 120 Schedule of Investment Properties 121 Corporate Governance Report 155 Risk Factors 159 Corporate Information and Key Dates Chairman’s Statement 2 CK Life Sciences Int’l., (Holdings) Inc. HK$ Million 2012 2011 Variance Turnover 4,545.0 3,511.6 +29% Agriculture-related 1,645.4 1,214.0 +36% Health 2,888.6 2,287.5 +26% Investment 11.0 10.1 +9% Profit attributable to shareholders 176.3 125.8 +40% For the year ended 31 December 2012, GROWTH IN AGRICULTURE-RELATED CK Life Sciences Int’l., (Holdings) Inc. (“CK Life BUSINESS THROUGH ACQUISITION Sciences” or the “Company”) achieved a strong performance. Profit attributable to shareholders of the CK Life Sciences’ agriculture-related business recorded Company increased 40% as compared to last year, a solid growth of 36% compared with the previous amounting to HK$176.3 million. year and reported a turnover of HK$1,645.4 million. The Board of Directors has recommended a final In February 2012, the Company’s agriculture-related dividend of HK$0.006 per share for the year ended business achieved a major milestone with the 31 December 2012 (HK$0.005 per share in 2011), a A$32.28 million (approximately HK$265 million) 20% increase over the previous year. The proposed acquisition of Peaty Trading Group (“Peaty”), the dividend will be paid on 5 June 2013 following second largest supplier of products and services in approval at the 2013 Annual General Meeting to those the professional turf management industry and the shareholders whose names appear on the Register of pest management industry in Australia. Following the Members of the Company at the close of business on completion of the transaction, the businesses were 24 May 2013. consolidated under the Company’s Amgrow Pty Ltd. CK Life Sciences is now one of the largest suppliers of agricultural products and services in Australia, particularly in turf management, home garden products and pest management. Annual Report 2012 3 Chairman’s Statement (Cont’d) CK Life Sciences further expanded its vineyard portfolio The nutraceutical portfolio comprising Santé Naturelle in October 2012 through the acquisition of 3 vineyards A.G. Ltée (“Santé Naturelle”) in Canada, Vitaquest in Western Australia’s Margaret River for International Holdings LLC (“Vitaquest”) in the United A$10.04 million (approximately HK$81 million). States, and Lipa Pharmaceuticals Limited (“Lipa”) in Like our other vineyard investments, these premium Australia all performed well, recording sales and profit vineyards are backed by long-term tenancies, and are increases. poised to contribute a steady and recurrent income to CK Life Sciences. Altogether, CK Life Sciences’ vineyard During the year, Santé Naturelle introduced new portfolio now features total area amounting to about products, strengthening their market share in key 6,500 hectares (approximately 700 million sq. ft.). product segments; while both Vitaquest and Lipa It is currently the second largest vineyard owner in completed expanding their facilities to increase Australasia. production capabilities. In November 2012, CK Life Sciences entered into GOOD PROGRESS IN an agreement to acquire Cheetham Salt Limited PHARMACEUTICAL R&D (“Cheetham”), Australia’s largest domestic producer of salt, for A$150 million (approximately HK$1.2 billion). CK Life Sciences’ pharmaceutical R&D initiatives Cheetham’s salt fields and refineries are spread over continued to make good progress during the year about 9,300 hectares (approximately 1 billion sq. ft.) under review. of leasehold and freehold land in Australia and New Zealand, of which around 90% is in Australia. The Research on the cancer vaccine for the treatment of transaction was completed in February 2013. The melanoma by the Company’s U.S. subsidiary Polynoma acquisition of Cheetham would bring to CK Life LLC (“Polynoma”) achieved a new milestone. In Sciences the opportunity to enter another stable January 2012, the U.S. Food and Drug Administration industry, expand land ownership profile and obtain (FDA) accepted Polynoma’s Investigational New Drug access to a new flow of steady and immediate returns. application for Phase III clinical testing of its melanoma vaccine in the United States, making CK Life Sciences Other operations in Australia, Mainland China and Asia one of the few Asian companies to obtain clearance continued to achieve a steady performance in 2012. from the FDA to commence Phase III clinical testing of a new drug. Patient enrollment for the adaptive NUTRACEUTICAL BUSINESS Phase III clinical trial has already commenced and is MAINTAINS GOOD PERFORMANCE progressing well. The Company’s nutraceutical business reported turnover of HK$2,888.6 million in 2012, an increase of 26% compared to last year. 4 CK Life Sciences Int’l., (Holdings) Inc. CK Life Sciences has been studying a number of With cash on hand of HK$572 million and a net debt options to recognise and enhance the value of the to net total capital ratio of 25.02%, we will continue melanoma vaccine via a number of avenues including to advance our existing businesses by seeking new the possibility of issuing an Initial Public Offering. opportunities that can bring secure and steady income to the Company. In 2012, the Phase III clinical trial of WEX Pharmaceuticals Inc.’s tetrodotoxin (“TTX”)-based pain CK Life Sciences has progressed well during 2012, and management product for the treatment of cancer we will continue to build on this successful platform to pain continued in Canada. At the same time, patient deliver further growth in the coming year. enrollment has commenced in the United States for a Phase II clinical trial to evaluate TTX for chemotherapy- I would like to take this opportunity to thank our induced neuropathic pain. shareholders, Board of Directors and staff for their on-going support. PROSPECTS We are confident about the future prospects of CK Life Sciences. Li Tzar Kuoi, Victor Through the acquisitions of Peaty, 3 vineyards and Chairman Cheetham in Australia, the scope of our existing investment portfolio has been strengthened, and Hong Kong, 6 March 2013 the profitability of our agriculture-related business enhanced. Organic growth of our existing businesses is also poised to continue to contribute to our revenue stream. Annual Report 2012 5 Business Review 6 CK Life Sciences Int’l., (Holdings) Inc. Agriculture- related Business 2012 has been an exciting year for CK Life Sciences’ agriculture- related business. 3 new acquisitions were made during the year: (i) the A$32.28 million (approximately HK$265 million) Peaty Trading Group; (ii) 3 vineyards in Margaret River for a consideration of A$10.04 million (approximately HK$81 million); and (iii) the A$150 million (approximately HK$1.2 billion) Cheetham Salt Limited. Annual Report 2012 7 Business Review (Cont’d) A majority of the vineyards in CK Life Sciences’ portfolios are committed to long-term leases with major Australasian wine companies, generating steady cashflows for the Company. VINEYARD BUSINESSES In 2012, Belvino extended the terms of existing leases on a number of vineyards held by a major tenant to further CK Life Sciences has two vineyard portfolios: secure its income streams. BELVINO PORTFOLIO NON-BELVINO PORTFOLIO CK Life Sciences acquired a 72.26% interest in Challenger 100% CK Life Sciences owned vineyards are held in a Wine Trust (“CWT”), a listed Australian unit trust, in number of vehicles outside of Belvino, including the 2011. Following the acquisition, CWT was de-listed and Qualco West vineyard purchased in 2011, and 3 vineyards renamed Belvino Investments Trust (“Belvino”). There are in Margaret River acquired in October 2012. 15 vineyards in Belvino’s portfolio, along with irrigation water entitlements. Together, these cover around 4,838 Spanning some 510 hectares (approximately 55 million hectares (approximately 521 million sq. ft.) of land in sq. ft.) of land, the Qualco West vineyard is located in the Australasia. Riverland Wine Region in South Australia. The Riverland wine region is Australia’s largest wine grape producing region. 8 CK Life Sciences Int’l., (Holdings) Inc. The 3 vineyards in Margaret River comprise the Old With a history dating back to 1888, Cheetham is Land Vineyard, the Rowe Road Vineyard and the Lionel Australasia’s largest producer of salt for domestic Vineyard. Located in a premium wine-growing region consumption. It has a production capacity of 3 hours south of Perth in Western Australia, these approximately 800,000 tonnes of crude salt and the 3 vineyards cover a total area of approximately 300 ability to convert up to 600,000 tonnes of this into hectares (approximately 32 million sq.
Load more

Recommended publications
  • Annual Report 2006 Annual Report2006
    (incorporated in the Cayman Islands with limited liability) (Stock Code: 8222) Better Health Better Life Annual Report 2006 Annual Report2006 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong Tel: (852) 2126 1212 Fax: (852) 2126 1211 www.ck-lifesciences.com Characteristics of the Growth Enterprise Market (”GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profi tability nor any obligation to forecast future profi tability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the This annual report (“Annual Report”) is available in both decision to invest only after due and careful consideration. English and Chinese. Shareholders who have received either The greater risk profi le and other characteristics of GEM the English or the Chinese version of the Annual Report mean that it is a market more suited to professional and other may request a copy in the language different from that has sophisticated investors. been received by writing to: Computershare Hong Kong Investor Services Limited, 46th Floor, Hopewell Centre, 183 Given the emerging nature of companies listed on GEM, there Queen’s Road East, Hong Kong. is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main The Annual Report (in both English and Chinese versions) Board and no assurance is given that there will be a liquid has been posted on the Company’s website at market in the securities traded on GEM.
    [Show full text]
  • Enhancing Everyday Living
    (Incorporated in the Cayman Islands with limited liability) (Stock Code: 0775) Annual Report 2017 Enhancing Everyday Living PHARMACEUTICAL 2 Dai Fu Street, Tai Po Industrial Estate, Hong Kong Tel: (852) 2126 1212 Fax: (852) 2126 1211 NUTRACEUTICAL www.ck-lifesciences.com Annual Report 2017 AGRICULTURE–RELATED About CK Life Sciences CK Life Sciences Int’l., (Holdings) Inc. is listed on The Stock Exchange of Hong Kong Limited. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in, products and assets which fall into three core categories – nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group. Contents 2 Chairman’s Statement 6 Business Review Agriculture-related Business Nutraceutical Business Pharmaceutical Business 24 Long Term Development Strategy 25 Financial Summary 26 Financial Review 28 Directors and Key Personnel 35 Report of the Directors 46 Independent Auditor’s Report 52 Consolidated Income Statement 53 Consolidated Statement of Comprehensive Income 54 Consolidated Statement of Financial Position 56 Consolidated Statement of Changes in Equity 57 Consolidated Statement of Cash Flows 59 Notes to the Consolidated Financial Statements 124 Principal Subsidiaries 129 Principal Joint Ventures 130 Schedule of Major Investment Properties 131 Corporate Governance Report 163 Environmental, Social and Governance Report 173 Risk Factors 178 Corporate Information and Key Dates Chairman’s Statement 2 CK Life Sciences Int’l., (Holdings) Inc. For the year ended 31 December 2017, CK Life Sciences Int’l., (Holdings) Inc. (“CK Life Sciences” or the “Company”) reported profit attributable to shareholders of HK$258 million, an increase of 2% as compared to the Company’s restated profit1 in 2016.
    [Show full text]
  • ENHANCING EVERYDAY LIVING Annual Report 2020
    (Incorporated in the Cayman Islands with limited liability) (Stock Code: 0775) Agriculture-related ENHANCING EVERYDAY LIVING Annual Report 2020 Nutraceutical Pharmaceutical ABOUT CK LIFE SCIENCES CK Life Sciences Int’l., (Holdings) Inc. is listed on The Stock Exchange of Hong Kong Limited. Bearing the mission of improving the quality of life, CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in products and assets which fall into three core categories – nutraceuticals, pharmaceuticals and agriculture-related. CK Life Sciences is a member of the CK Hutchison Group. Contents 2 Chairman’s Statement 6 Business Review Agriculture-related Business Nutraceutical Business Pharmaceutical Research 24 Long Term Development Strategy 25 Financial Summary 26 Financial Review 28 Directors and Key Personnel 36 Report of the Directors 48 Independent Auditor’s Report 54 Consolidated Income Statement 55 Consolidated Statement of Comprehensive Income 56 Consolidated Statement of Financial Position 58 Consolidated Statement of Changes in Equity 59 Consolidated Statement of Cash Flows 61 Notes to the Consolidated Financial Statements 121 Principal Subsidiaries 125 Principal Joint Venture 126 Schedule of Major Investment Properties 127 Corporate Governance Report 163 Risk Factors 170 Corporate Information and Key Dates Chairman's Statement 2 CK Life Sciences Int'l., (Holdings) Inc. For the year ended 31 December 2020, CK Life took the opportunity to restructure the organisation Sciences Int’l., (Holdings) Inc. (“CK Life Sciences” or the and implement improvements which could facilitate “Company”) reported profit attributable to shareholders post-pandemic growth, including the commissioning of a of HK$125 million, a decrease of about 31% as compared new production facility, installation of new machines and to that of 2019 mainly due to the impact caused by implementation of software to streamline and promote COVID-19.
    [Show full text]
  • Principal Subsidiary and Associated Companies and Joint Ventures at 31 December 2020
    Principal Subsidiary and Associated Companies and Joint Ventures at 31 December 2020 Nominal value of Place of incorporation / issued ordinary Percentage of Subsidiary and associated companies and principal place of share capital **/ equity attributable joint ventures operations registered capital to the Group Principal activities Ports and related services Alexandria International Container Terminals Egypt USD 30,000,000 59 Container terminal operating Company S.A.E. Amsterdam Container Terminals B.V. Netherlands EUR 18,400 80 Container terminal operating Brisbane Container Terminals Pty Limited Australia AUD 34,100,000 80 Container terminal operating Buenos Aires Container Terminal Services S.A. Argentina ARS 648,385,014 80 Container terminal operating ECT Delta Terminal B.V. Netherlands EUR 18,000 71 Container terminal operating Ensenada Cruiseport Village, S.A. de C.V. Mexico MXP 145,695,000 80 Cruise terminal operating Ensenada International Terminal, S.A. de C.V. Mexico MXP 160,195,000 80 Container terminal operating Europe Container Terminals B.V. Netherlands EUR 45,000,000 75 Holding company Euromax Terminal Rotterdam B.V. Netherlands EUR 100,000 49 Container terminal operating Freeport Container Port Limited Bahamas BSD 2,000 41 Container terminal operating Gdynia Container Terminal S.A. Poland PLN 11,379,300 80 Container terminal operating and rental of port real estate Harwich International Port Limited United Kingdom GBP 16,812,002 80 Container terminal operating ✡ Hongkong United Dockyards Limited Hong Kong HKD 76,000,000 50 Ship repairing, general engineering and tug operations ✡ 惠州港業股份有限公司 China RMB 300,000,000 27 Container terminal operating ✡ Huizhou Quanwan Port Development Co., Ltd.
    [Show full text]
  • Solid Foundation Fosters Long-Term Development
    20 1 7 Annual Report Solid Foundation Fosters Long-term Development 22nd Floor, Hutchison House, 10 Harcourt Road, Hong Kong Telephone: +852 2128 1188 2017 Annual Report Facsimile: +852 2128 1705 www.ckh.com.hk WorldReginfo - 7a0610cc-4251-4d12-8195-61d40b71508e Corporate Information CK Hutchison Holdings Limited BOARD OF DIRECTORS EXECUTIVE DIRECTORS NON-EXECUTIVE DIRECTORS Chairman CHOW Kun Chee, Roland, LLM LI Ka-shing, GBM, KBE, LLD (Hon), DSSc (Hon) CHOW WOO Mo Fong, Susan, BSc Commandeur de la Légion d’Honneur Grand Officer of the Order Vasco Nunez de Balboa LEE Yeh Kwong, Charles, GBM, GBS, OBE, JP Commandeur de l’Ordre de Léopold LEUNG Siu Hon, BA (Law) (Hons), LL.D. (Hon) Group Co-Managing Director and George Colin MAGNUS, OBE, BBS, MA Deputy Chairman LI Tzar Kuoi, Victor, BSc, MSc, LLD (Hon) INDEPENDENT NON-EXECUTIVE DIRECTORS Group Co-Managing Director KWOK Tun-li, Stanley, BSc (Arch), AA Dipl, LLD (Hon), ARIBA, MRAIC FOK Kin Ning, Canning, BA, DFM, FCA (ANZ) CHENG Hoi Chuen, Vincent, GBS, OBE, JP Frank John SIXT, MA, LLL The Hon Sir Michael David KADOORIE, GBS, LLD (Hon), DSc (Hon) Group Finance Director and Deputy Managing Director Commandeur de la Légion d’Honneur Commandeur de l’Ordre des Arts et des Lettres IP Tak Chuen, Edmond, BA, MSc Commandeur de l’Ordre de la Couronne Deputy Managing Director Commandeur de l’Ordre de Leopold II (William Elkin MOCATTA, FCA as his alternate) KAM Hing Lam, BSc, MBA Deputy Managing Director LEE Wai Mun, Rose, JP, BBA LAI Kai Ming, Dominic, BSc, MBA William SHURNIAK, S.O.M., M.S.M., LLD
    [Show full text]
  • Board and Key Personnel
    BOARD AND KEY PERSONNEL Executive Committee Front (from left to right) Andrew Hunter, H L Kam, Victor Li, Edmond Ip Back (from left to right) Joanna Chen, Pak Lam Lun, Lambert Leung, Dominic Chan, Ivan Chan, Victor Luk, Wendy Tong Barnes DIRECTORS’ BIOGRAPHICAL INFORMATION LI Tzar Kuoi, Victor aged 47, has been the Chairman of the Company since its incorporation in May 1996. He has been a member of the Remuneration Committee of the Company since March 2005 and acted as the Chairman of the Remuneration Committee of the Company from March 2005 to December 2011. He is also the Managing Director and Deputy Chairman of Cheung Kong (Holdings) Limited, Deputy Chairman of Hutchison Whampoa Limited, the Chairman of CK Life Sciences Int’l., (Holdings) Inc., an Executive Director of Power Assets Holdings Limited, Co-Chairman of Husky Energy Inc. and a Director of The Hongkong and Shanghai Banking Corporation Limited (“HSBC”). Except for HSBC, all the companies mentioned above are listed companies. Mr. Victor Li serves as a member of the Standing Committee of the 11th National Committee of the Chinese People’s Political Consultative Conference of the People’s Republic of China. He is also a member of the Commission on Strategic Development and the Council for Sustainable Development of the Hong Kong Special Administrative Region (“HKSAR”), and Vice Chairman of the Hong Kong General Chamber of Commerce. Mr. Victor Li is also the Honorary Consul of Barbados in Hong Kong. He is a director of certain substantial shareholders of the Company within the meaning of Part XV of the Securities and Futures Ordinance (“SFO”), and a director of certain companies controlled by certain substantial shareholders of the Company.
    [Show full text]
  • E 8222Pro-20020704.Pdf
    IMPORTANT If you are in any doubt about this prospectus, you should consult your stockbroker, bank manager, solicitor, professional accountant or other professional adviser. A1 * PLACING AND PUBLIC OFFER Number of Offer Shares : 1,307,000,000 Shares (subject to under the Share Offer Over-allotment Option adjustment) Number of Placing Shares : 1,176,300,000 (subject to Over-allotment A15(1)(3) Option adjustment) (a) Number of Public Offer Shares : 130,700,000 (subject to reallocation) Offer Price : not more than HK$2.00 per Share A15(3)(c) payable in full on application Nominal Value : HK$0.10 each Sch3.I.9 Stock Code : 8222 A15(3)(c) LISTING ON THE GROWTH ENTERPRISE MARKET OF THE STOCK EXCHANGE OF HONG KONG LIMITED Global Co-ordinator, Sponsor and Lead Manager Co-Lead Managers BNP Paribas Peregrine BOCI Asia Limited CLSA / CIBC World Markets ICEA Capital Limited The Hongkong and Shanghai Banking Corporation Limited Co-Managers CEF Capital Limited China Everbright Capital Limited Core Pacific-Yamaichi International (H.K.) Limited FB Gemini Securities Ltd ING Bank N.V. SG Securities (HK) Ltd. South Capital Brokerage Limited Sun Hung Kai International Limited Worldsec International Limited The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this 14.04 prospectus, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever S.342C(2)(a) arising from or in reliance upon the whole or any part of the contents of this prospectus. A copy of this prospectus, having attached thereto the documents specified in the paragraph headed “Documents delivered to the Registrar of S.342C(1) Companies” in Appendix V, has been registered with the Registrar of Companies in Hong Kong as required by section 342C of the Companies S.342C(2)(b) Ordinance (Chapter 32 of the Laws of Hong Kong).
    [Show full text]
  • Daohengsecurities Ltd
    THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser. If you have sold or transferred all your shares in CK Life Sciences Int’l., (Holdings) Inc., you should at once hand this circular and the accompanying proxy form to the purchaser or the transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee. The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this circular, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular. (Incorporated in the Cayman Islands with limited liability) (Stock Code: 8222) PROPOSED ELECTION OF DIRECTORS AT THE ANNUAL GENERAL MEETING, PROPOSED GENERAL MANDATES TO ISSUE NEW SHARES AND REPURCHASE SHARES AND CONTINUING CONNECTED TRANSACTIONS – RENEWAL OF THE EXISTING CKH SUPPLY AGREEMENT AND THE EXISTING HIL SUPPLY AGREEMENT Independent financial adviser to the Independent Board Committee and the Independent Shareholders in relation to the Continuing Connected Transactions DaoHengSecurities Ltd. A proxy form for use at the Annual General Meeting of the Company to be held at the Ballroom, 1st Floor, Harbour Plaza Hong Kong, 20 Tak Fung Street, Hung Hom, Kowloon, Hong Kong on 12 May 2005 is enclosed with this circular.
    [Show full text]
  • CK Life Sciences Int'l., (Holdings) Inc
    CK Life Sciences Int’l., (Holdings) Inc. Annual Report 2002 Restoring Freshness to Nature Bringing Quality to Life 2 Dai Fu Street • Tai Po Industrial Estate • Hong Kong Tel (852) 2126 1212 Fax (852) 2126 1211 Website www.ck-lifesciences.com Annual Report 2002 Characteristics of the Growth Enterprise Market (“GEM”) of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) GEM has been established as a market designed to accommodate companies to which a high investment risk may be attached. In particular, companies may list on GEM with neither a track record of profitability nor any obligation to forecast future profitability. Furthermore, there may be risks arising out of the emerging nature of companies listed on GEM and the business sectors or countries in which the companies operate. Prospective investors should be aware of the potential risks of investing in such companies and should make the decision to invest only after due and careful consideration. The greater risk profile and other characteristics of GEM mean that it is a market more suited to professional and other sophisticated investors. Given the emerging nature of companies listed on GEM, there is a risk that securities traded on GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance is given that there will be a liquid market in the securities traded on GEM. The principal means of information dissemination on GEM is publication on the internet website operated by the Stock Exchange. Listed companies are not generally required to issue paid announcements in gazetted newspapers.
    [Show full text]
  • CK Hutchison Holdings Limited (CKHH) Facts and Figures
    CK Hutchison Holdings Limited (CKHH) Facts and Figures. The company. CK Hutchison Holdings Limited (CKHH) is not only one of the largest companies that are listed at the Hong Kong stock exchange, it is also one of the oldest trade companies in Hong Kong – its roots go back to the year 1820. The various business sectors and around 290,000 employees in over 50 countries make the conglomerate one of the world´s leading companies. Business sectors. HWL operates in 5 core businesses: Ports and related services. Hutchison Port Holdings runs all the company‘s ports and related services in 25 countries. Currently, HPH holds a share of 269 berths in 48 ports. Retail. AS Watson is the largest international health and beauty retailer in Asia and Europe and runs more than 13,300 retail stores in 22 countries worldwide, counting more than 130,000 employees. In Hong Kong and on the Chinese mainland, AS Watson is responsible for the production, distribution and bottling of different mineral waters and other drinks. In Europe, the Group operates a number of health & beauty retail brands, chains - Drogas, including Kruidvat, Superdrug, Rossmann, Savers, Trekpleister, Spektr and Watsons. In addition, it also owns two luxury perfumeries and cosmetics retail brands ICI PARIS XL and The Perfume Shop. Infrastructure. The company operates in Hong Kong, the Chinese mainland, Great Britain, the Netherlands, Portugal, Australia, New Zealand and Canada. Its core fields are energy infrastructure, water infrastructure, transportation infrastructure, waste management and aircraft leasing. Energy. HWL holds about 40,2 % of Canadian Husky Energy, an energy-related company listed on the Toronto Stock Exchange.
    [Show full text]
  • TASTY! CK HUTCHISON TICKLES YOUR TASTE BUDS a S Watson at 175 22 the Zen-Ity of Tsz Shan Monastery 14 Download Sphere Online the Future Is Now 20
    #41 2016 CK HUTCHISON GROUP TASTY! CK HUTCHISON TICKLES YOUR TASTE BUDS A S Watson at 175 22 The Zen-ity of Tsz Shan Monastery 14 Download Sphere online The future is now 20 #41 2016 CK HUTCHISON GROUP TASTY! CK HUTCHISON TICKLES YOUR TASTE BUDS A S Watson at 175 22 The Zen-ity of Tsz Shan Monastery 14 Download Sphere online The future is now 20 Sphere Magazine #41 WELCOME December 2016 Cover Illustration By Kaliz Lee GOODNESS PERSISTS Taste is a surprisingly complex business. From simple juices to complex wines and healthy foods, IN A CHANGING WORLD our artist captures the moment of truth for many Offtimes, the world can seem a turbulent, easy for people to make wise choices of our businesses --- what happens when the taste topsy-turvy place. Old ways and old in an often confusing world. hits your tongue! institutions are questioned as their relevance seems to wane in the face of new challenges. Religious traditions can also provide guidance, continuity and serenity in a But some organisations adapt, grow and changing world. The Tsz Shan Monastery advance. The CK Hutchison Group is such not only provides modern architecture an organisation, and new technologies, in temples with ancient themes, but also new jobs and new opportunities emerge conducts contemporary outreach to work every day to the benefit of our employees, directly with people in Hong Kong’s urban customers, partners and communities. rough patches, to heal lives and souls. Within the Group, A S Watson is an While avoiding hubris, we can recognise exemplar of benevolent continuity as that this force for good arises from well- it reaches the milestone of 175 years in meaning and hard-working people with business.
    [Show full text]
  • Cowries to Computers Life in the Fro-Zone 14 Salty, So Sweet 20 LKSF Catalyst for Chinese-Israeli Connection 22 Present
    #44 2018 Download Sphere online 1200 BC 300 AD 627 1736 1860s 1950s MONEY: COWRIES TO COMPUTERS Life in the Fro-Zone 14 Salty, So Sweet 20 LKSF Catalyst for Chinese-Israeli Connection 22 PRESENT The ancient becomes new again. Sphere Magazine #44 March 2018 WELCOME Cover Illustration Jessica Li Whatever you call it THE BEST OLD or however you carry it, money has always been crucial to the most modern and most IS NEW primitive civilisations. The cover illustration captures its many manifestations. The newest, best things are sometimes the One of ancient man’s great foes is still with oldest things imaginable. They survive for us – absolute freezing cold. But this less than millennia because they don’t stay old. The great thing has been overcome since the ancient becomes new, transformed by the Inuit’s forebears crossed the Bering Strait hand of man, again and again. and the Sami people colonised Lapland. Now, CKHH companies from Husky Energy Take money. From using AlipayHK by a to 3 Sweden and Park’N Fly not only survive, swipe of your mobile phone to the first- but thrive in the face of killer bears, killer ever coin, the Lydian Lion, money is an icicles and killer cold conditions. Ancient idea on a par with the invention of the man and modern business have conquered wheel for its importance to civilisation. the fro-zone. But while the Tang dynasty’s first attempts at paper money may not be visible on While education may be a recent invention your smartphone today, the idea is there.
    [Show full text]